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As cases of antibiotic resistant bacteria increase, 
possible alternatives to antibiotics have often 
been sought. One alternative discussed in 
literature is phage therapy. While this procedure 
has been studied for many decades, there is 
still much to learn for such a practice to become 
commonplace. For the purpose of this review, 
Pseudomonas aeruginosa will be discussed, 
since it often exhibits antibiotic resistance in 
hospitals.
Phage Therapy Explained
Bacteriophages are the most abundant 
‘organisms’ on Earth.Phages are viruses that 
specifically attach to and infect bacteria. Each 
virus is specific to a particular strain/s of the 
bacterium and can either be lytic (infects and 
kills the cell) or lysogenic (incorporating its 
genetic material into the genetic material of the 
bacteria) (Clokie et al., 2011). Bacteriophages 
are an extremely diverse group of viruses with 
vastly different morphologies and families. 
While siphoviruses, for example,  have no 
envelopes and have long tails, ampullaviruses 
are enveloped and bottle-shaped (Kulikov et al., 
2007).
Phage therapy targets bacterial infections in 
the body by making use of bacteriophages 
(Lin et al., 2017).The process was discussed as 
far back as 1915 (Twort., 1915) but following 
the discovery of penicillin, research was mostly 
stopped except in the Soviet Union and Eastern 
Europe, where it has occasionally been used 
(Wittebole et al., 2013). 
Only lytic bacteriophages (i.e. those that 
cause quick bacterial cell death) are used in 
phage therapy. Lysogenic phages make their 
genetic material available to the bacteria to be 
transcribed. Such genes may actually help the 
bacteria by producing virulence factors (like 
botulinum toxin) or antibiotic resistance genes 
(Ohnishi et al., 2001).
Advantages of Phage Therapy over 
Antibiotic Treatment
Phage therapy has a number of strengths over 
antibiotics. Primarily, they are very specific to 
one or a few bacterial strains that carry their 
complement receptor and will not attack other 
important bacteria such as gut flora. Therefore, 
side effects are typically minimal and chances 
of opportunistic infections are reduced.Phages 
are mostly proteins and nucleic acids and are 
therefore nontoxic (Loc-Carrillo et al., 2011). 
They also self-amplify (so very small doses 
are needed) and are very useful in biofilm 
degradation (Donlan., 2009).Phages can be 
administered in many different ways and are 
versatile even with regards to formulation 
development.  They are easy to discover as they 
are usually found in waste products with high 
bacterial concentrations (Kutateladze et al., 
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Immediate Problems Associated with Phage 
Therapy
The specificity of phagescan sometimes be 
problematic since the strain of bacteria must 
be specific too and thus, a ‘phage cocktail’ 
of multiple phages is often used to ensure 
adequate treatment (Watanabe et al., 2006). 
Phagescan sometimes cause immune system 
activation including possible cytokine release 
though little evidence exists that this could 
happen during phage therapy. Still, in order 
to prevent anaphylaxis, highly purified phages 
must be prepared and complete isolation of 
bacteriophages can be difficult (Loc-Carrillo et 
al., 2011).
P.aeruginosaInfection Characteristics
Pseudomonas aeruginosa (PA) is a gram-
negative, opportunistic, environmental 
pathogen. It especially infects patients in 
hospitals and can be a life-threatening infection 
since some strains have shown resistance to 
a large number of antibiotics(CDC., 2019).It 
can lead to infection of critical body organs, 
as well as sepsis and is notably often found in 
patients suffering from cystic fibrosis. (Rossitto 
et al., 2018). The infection is also associated 
with mechanical heart valves, grafts, sutures 
and catheter-associated urinary tract infections.
The bacterium can survive on many different 
environmental surfaces (Remold et al., 2011) 
andresistance to antibiotics has been linked to 
increased hospital stay and morbidity (de Kraker 
et al., 2011). PA owes its antibiotic resistance 
to a series of multi-drug efflux (Mex) systems 
which pump antibiotics out of the bacterial cell 
(Masuda et al., 2000).
Using Phage Therapy to Treat PA Infections
Phage therapy has shown mixed results when 
applied to PA infections. Phage OMKO1 is an 
example of a bacteriophage targeting PA. It 
uses the outermembrane protein M associated 
with the multidrug efflux systems MexAB and 
MexXY to bind to its host. One study involved 
an aortic graft infected with PA. Following 
endotoxin removal from the phage solution, 
10 ml of phage OMKO1 (10e7 PFU/ml) and 
ceftazidime (0.2 g/ml) solution was administered 
into the mediastinal fistula. The next day, the 
patient had improved markedly and soon 
was able to return home. Biofilms grown with 
P.aeruginosa  isolated from the graft showed 
that treatment with OMKO1 both alone and 
with antibiotic significantly reduced bacterial 
densities compared to the antibiotic alone.  
(Chan et al., 2019).
PA phage therapy has also been successfully 
used to prevent intestinal colonisation and 
overgrowth in young children in Georgia 
(Chanishvili et al., 2008) as well as prevention 
and degradation of biofilm in a hospital setting 
(Motlagh et al., 2016).5 podoviruses and a 
myovirus have also been used to treat chronic 
otitis infections with no observed serious side 
effects  (Kutter et al., 2010).
Another study showed that fish embryos 
infected with P.aeruginosa showed a strong 
reduction in lethality when administered both 
phages and ciprofloxacin compared to either 
one of the two (Cafora et al., 2019). Yet another 
bacteriophage (KPP10) was administered 
to mice suffering from gut-derived sepsis 
due to PA. Intravenous and intraperitoneal 
administration were found to be more effective 
but whilst KPP10 did reduce mortality, it did so 
best if administered 1 day after inoculation with 
the bacteria (Watanabe et al., 2007).
That being said, phage resistance has often 
been put forward as a possible problem 
associated with phage therapy. Indeed, OMKO1 
binding to its MexAB and MexXY systems 
pushes for selection of bacteria to evolve phage 
resistance. However, a study did note that such 
resistance actually causes changes in the Mex 
systems causing the bacterium to lose some 
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antibiotic resistance. As such, a bacteriophage 
cocktail administered with an antibiotic is ideal 
(Chan et al., 2016). Another approach involves 
the isolation of endolysins like artylisins from 
bacteriophages. Once again, this has been 
shown to kill PA in situ (Briers et al., 2014).
Whilst so far, most studies on phage therapy 
have been case studies carried out in Eastern 
Europe, the European Commission is now 
funding a project called ‘Phagoburn’ which 
will be organising the world’s first multicentre, 
randomised controlled trials (Phagoburn., 
2019).  The first such study took place with 
patients who had infected burn wounds. A 
phage cocktail or PP1131 was found not to be 
as effective as silver sulfadiazine at treating the 
wound. That being said, the therapy was also 
associated with less side effects than the silver 
sulfadiazine. It is possible that this negative 
result was obtained because too little phage 
was used.  More research is required (Jault et 
al., 2019).
Discussion:
Phage therapy certainly has the potential to 
become a more commonplace procedure in 
infection treatment. That being said, a lot more 
research (especially controlled, unbiased trials) 
in the field is merited. Whilst most research 
traditionally took place in Eastern Europe, 
researchers in countries like the United States 
(Furr et al., 2018) and Belgium (Jennes et al., 
2017) are also seriously beginning to take 
an interest. Only further study about safety 
concerns, costs and efficacy of phage therapy 
can lead to the possibility of such a procedure 
becoming more mainstream.
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